A
Acrivon Therapeutics D
D
ACRV
1.84000
USD
0.14
(8.24%)
Post Trading·1.87000USD+0.03000(+1.63%)
Volume
10,232
EPS
-2
Div Yield
-
P/E
-1
Market Cap
78,850,186
Articles
Title: Acrivon Therapeutics
Sector: Healthcare
Industry: Biotechnology
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response andcell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.




